Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4513-4518

  Cushion, Melanie T ^a,b   Collins, Margaret S ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CONTROLLED STUDY; FUNGUS CULTURE; IN VITRO STUDY; NONHUMAN; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; SERUM;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS INFECTIONS; RATS;

EID: 80052845064     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00017-11     Document Type: Article

References (38)

1. Bachmann, S. P., et al. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
2. Beltz, K., et al. 2006. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin. Padiatr. 218:177-179.
3. Chandra, J., et al. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394.
4. Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens. 2000. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. 44:3302-3305.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cushion, M. T., F. Chen, and N. Kloepfer. 1997. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob. Agents Chemother. 41:379-384. (Pubitemid 27111034)
7. Cushion, M. T., M. Collins, B. Hazra, and E. S. Kaneshiro. 2000. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother. 44:713-719.
8. Cushion, M. T., M. S. Collins, and M. J. Linke. 2009. Biofilm formation by Pneumocystis spp. Eukaryot. Cell 8:197-206.
9. Cushion, M. T., et al. 2010. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving significant trophic burdens that cannot transmit the infection. PLoS One 5(1):e8524.
10. Cushion, M. T., J. J. Ruffolo, M. J. Linke, and P. D. Walzer. 1985. Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Exp. Parasitol. 60:43-54.
11. Cushion, M. T., and P. D. Walzer. 2009. Preclinical drug discovery for new anti-Pneumocystis compounds. Curr. Med. Chem. 16:2514-2530.
12. Cushion, M. T., et al. 2006. In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice. Antimicrob. Agents Chemother. 50:2337-2343. (Pubitemid 43993171)
13. Di Bonaventura, G., et al. 2006. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob. Agents Chemother. 50:3269-3276.
14. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
15. Hof, H., and P. Schnulle. 2008. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 51(Suppl. 1):65-67.
16. Joffrion, T. M., and M. T. Cushion. 2010. Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii. FEMS Microbiol. Lett. 311:1-9.
17. Kaneshiro, E. S., M. S. Collins, and M. T. Cushion. 2000. Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother. 44:1630-1638.
18. Kaur, N., and T. C. Mahl. 2004. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig. Dis. Sci. 49: 1458-1460.
19. Kaur, N., and T. C. Mahl. 2007. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 52:1481-1484.
20. Martinez, L. R., and A. Casadevall. 2006. Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect. Immun. 74:6118-6123.
21. Martinez, L. R., and A. Casadevall. 2006. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 50:1021-1033.
22. Miceli, M. H., S. M. Bernardo, and S. A. Lee. 2009. In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms. Int. J. Antimicrob. Agents 34:500-502.
23. Morris, A., et al. 2004. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am. J. Respir. Crit. Care Med. 170:408-413. (Pubitemid 39214615)
24. Mowat, E., et al. 2008. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62:1281-1284.
25. Nett, J. E., K. M. Guite, A. Ringeisen, K. A. Holoyda, and D. R. Andes. 2008. Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob. Agents Chemother. 52:3411-3413.
26. Odabasi, Z., V. Paetznick, J. H. Rex, and L. Ostrosky-Zeichner. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51:4214-4216.
27. Pierce, C. G., et al. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500.
28. Pound, M. W., M. L. Townsend, and R. H. Drew. 2010. Echinocandin pharmacodynamics: review and clinical implications. J. Antimicrob. Chemother. 65:1108-1118.
29. Ramage, G., S. P. Saville, D. P. Thomas, and J. L. Lopez-Ribot. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638.
30. Ramage, G., W. K. Vande, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
31. Ramage, G., K. Vandewalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.
32. Rex, J. H., et al. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
33. Shuford, J. A., K. E. Piper, J. M. Steckelberg, and R. Patel. 2007. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn. Microbiol. Infect. Dis. 57:277-281. (Pubitemid 46330658)
34. Tobudic, S., C. Kratzer, A. Lassnigg, W. Graninger, and E. Presterl. 2010. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65:271-274.
35. Utili, R., et al. 2007. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation 84:685-688. (Pubitemid 47480652)
36. Vediyappan, G., T. Rossignol, and C. d'Enfert. 2010. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob. Agents Chemother. 54:2096-2111.
37. Waters, L., and M. Nelson. 2007. The use of caspofungin in HIV-infected individuals. Expert. Opin. Invest. Drugs. 16:899-908.
38. Wiederhold, N. P., et al. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620.